HC Wainwright Boosts Femasys (NASDAQ:FEMY) Price Target to $15.00

Femasys (NASDAQ:FEMY) had its price target hoisted by stock analysts at HC Wainwright from $12.00 to $15.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Femasys Price Performance

NASDAQ FEMY opened at $1.60 on Wednesday. The firm’s fifty day simple moving average is $1.36 and its two-hundred day simple moving average is $1.21. The company has a current ratio of 3.94, a quick ratio of 3.26 and a debt-to-equity ratio of 0.86. Femasys has a 12-month low of $0.86 and a 12-month high of $1.84. The firm has a market capitalization of $36.64 million, a P/E ratio of -1.98 and a beta of -2.85.

Institutional Investors Weigh In On Femasys

A number of large investors have recently made changes to their positions in FEMY. XTX Topco Ltd grew its holdings in shares of Femasys by 123.9% during the third quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock valued at $36,000 after buying an additional 18,004 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Femasys by 9.2% during the third quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock valued at $229,000 after buying an additional 17,473 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Femasys during the fourth quarter valued at $25,000. Northern Trust Corp grew its holdings in shares of Femasys by 42.6% during the fourth quarter. Northern Trust Corp now owns 126,096 shares of the company’s stock valued at $139,000 after buying an additional 37,675 shares during the last quarter. Finally, Jane Street Group LLC purchased a new stake in shares of Femasys during the fourth quarter valued at $30,000. 65.27% of the stock is owned by hedge funds and other institutional investors.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.